公开(公告)号：US11559566B2

公开(公告)日：2023-01-24

申请号：US16925983

申请日：2020-07-10

申请人： INSERM (Institut National de la Sante et de la Recherche Medicale) ,  ASSISTANCE PUBLIQUE HOPITAUX DE PARIS ,  SORBONNE UNIVERSITE

发明人： David Klatzmann ,  David Saadoun ,  Patrice Cacoub ,  Michèle Rosenzwajg ,  Eliane Piaggio ,  Gilbert Bensimon ,  Claude Bernard

IPC分类号： A61K38/20

摘要： The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.

公开(公告)号：US20190351023A1

公开(公告)日：2019-11-21

申请号：US16361902

申请日：2019-03-22

申请人： INSERM (Institut National de la Sante et de la Recherche Medicale) ,  Assistance Publique - Hopitaux De Paris ,  SORBONNE UNIVERSITE

发明人： David Klatzmann ,  David Saadoun ,  Patrice Cacoub ,  Michèle Rosenzwajg ,  Eliane Piaggio ,  Gilbert Bensimon ,  Claude Bernard

IPC分类号： A61K38/20

摘要： The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.

公开(公告)号：US10293028B2

公开(公告)日：2019-05-21

申请号：US15588226

申请日：2017-05-05

申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) ,  Assistance Publique—Hopitaux De Paris ,  SORBONNE UNIVERSITE

发明人： David Klatzmann ,  David Saadoun ,  Patrice Cacoub ,  Michéle Rosenzwajg ,  Eliane Piaggio ,  Gilbert Bensimon ,  Claude Bernard

IPC分类号： A61K38/20

摘要： The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.

公开(公告)号：US20240335510A1

公开(公告)日：2024-10-10

申请号：US18746819

申请日：2024-06-18

申请人： CENTRE HOSPITALIER UNIVERSITAIRE DE NIMES ,  HUMANITAS MIRASOLE SPA ,  The University of Sussex ,  King's College London ,  Queen Mary University of London ,  Sorbonne Universite ,  Assistance Publique-Hopitaux De Paris ,  The University of Sheffield

发明人： Gilbert Bensimon ,  Peter Nigel Leigh ,  Timothy Tree ,  Cecilia Garlanda ,  Massimo Locati ,  Janine Kirby ,  Pamela Shaw ,  Andrea Malaspina

IPC分类号： A61K38/20 ,  A61K31/428 ,  A61P25/28

CPC分类号： A61K38/2013 ,  A61K31/428 ,  A61P25/28

摘要： The present invention is in the field of amyotrophic lateral sclerosis (ALS) and relates to human interleukin-2 (IL-2) for use in the treatment of amyotrophic lateral sclerosis in a human subject, wherein each dose of human IL-2 administered to said subject is between 0.1×106 to 3×106 international units (IU). Human IL-2 is preferably administered in cycles of 3 to 7 days of once-daily sub-cutaneous injection of 0.1×106 to 3×106 IU human IL-2. The treatment does not comprise the administration of regulatory T cells to the subject, who is preferably also under riluzole treatment. The administered human IL-2 is preferably not complexed with anti-hIL-2 antibodies and the treatment also preferably does not comprise the administration of rapamycin or any other suppressive agent of effector T cells (Teffs) to the subject. The treatment permits to decrease plasma CCL2 concentration and to change the polarization of blood macrophages from an M1 inflammatory phenotype to an anti-inflammatory M2 phenotype involved in tissue repair.

公开(公告)号：US10765723B2

公开(公告)日：2020-09-08

申请号：US16361902

申请日：2019-03-22

申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) ,  Assistance Publique—Hopitaux De Paris ,  SORBONNE UNIVERSITE

发明人： David Klatzmann ,  David Saadoun ,  Patrice Cacoub ,  Michèle Rosenzwajg ,  Eliane Piaggio ,  Gilbert Bensimon ,  Claude Bernard

IPC分类号： A61K38/20

摘要： The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.

公开(公告)号：US20170304402A1

公开(公告)日：2017-10-26

申请号：US15588226

申请日：2017-05-05

申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) ,  Assistance Publique - Hopitaux De Paris ,  Universite Pierre et Marie Curie (PARIS 6)

发明人： David Klatzmann ,  David Saadoun ,  Patrice Cacoub ,  Michèle Rosenzwajg ,  Eliane Piaggio ,  Gilbert Bensimon ,  Claude Bernard

IPC分类号： A61K38/20

CPC分类号： A61K38/2013

摘要： The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.